Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03088826 · ClinicalTrials.gov registry record · Phase 2
Analgesic Efficacy of (MSIR)/Acetaminophen vs. Oxycodone/Acetaminophen (Percocet)
A Phase 2 study, sponsored by Antonios Likourezos.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT03088826 is a Phase 2 study that has completed, run by Antonios Likourezos. The registered enrollment target is 80 participants.
The verdict
NCT03088826, a Phase 2 study, has completed, sponsored by Antonios Likourezos.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
Oxycodone and Hydrocodone are the most commonly used oral opioid analgesics in the emergency department and in outpatient settings. Both medications have a very high potential for abuse due to the prominence of the euphoric effect (abuse liability) and relative lack of "bad "or "negative" effects (likeability). The highly addictive properties of these medications lead to recurrent ED visits for repetitive dosing and prescribing that may lead to abuse, misuse, development of dependence and addiction, and, most importantly, death due to overdose. In contrast, several research papers demonstrated that administration of MSIR results in similar analgesic efficacy to Oxycodone and Hydrocodone but with significantly less euphoric and rewarding associated effects. In addition, consumption of large doses of MSIR leads to dysphoria, vomiting and sedation ("negative effects"). To the investigators' knowledge, there are no randomized controlled trials in the ED that directly compared analgesic efficacy of MSIR to Percocet
Interventions
- DRUG Acetaminophen
- DRUG Oxycodone
- DRUG Morphine Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-08-18 |
| Est. Completion | 2020-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03088826
The ClinicalTrials.gov registry entry for NCT03088826 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Antonios Likourezos, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Acetaminophen is the first listed.
NCT03088826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03088826 about?
NCT03088826 is a clinical study titled "Analgesic Efficacy of (MSIR)/Acetaminophen vs. Oxycodone/Acetaminophen (Percocet)". Oxycodone and Hydrocodone are the most commonly used oral opioid analgesics in the emergency department and in outpatient settings. Both medications have a very high potential for abuse due to the prominence of the euphoric effect (abuse liability) and relative lack of "bad "or "negative" effects (l...
What is the current status of trial NCT03088826?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2017-08-18. Estimated completion is 2020-12-22.
What interventions are being tested in trial NCT03088826?
The interventions under investigation include: Acetaminophen (DRUG), Oxycodone (DRUG), Morphine Sulfate (DRUG).
Who is sponsoring clinical trial NCT03088826?
This trial is sponsored by Antonios Likourezos, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.